- Home
- SAMO vs ZNTL Comparison
SAMO vs ZNTL Comparison
Compare SAMO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.21
Company Overview
Basic Information| Metric | SAMO | ZNTL |
|---|---|---|
| Founded | 2026 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.8M | 289.0M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SAMO | ZNTL |
|---|---|---|
| Price | $9.80 | $2.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $7.44 |
| AVG Volume (30 Days) | 83.1K | ★ 1.3M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.80 | $1.21 |
| 52 Week High | $9.85 | $6.95 |
Technical Indicators
Market Signals| Indicator | SAMO | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 33.89 |
| Support Level | $9.80 | $2.09 |
| Resistance Level | $9.83 | $2.76 |
| Average True Range (ATR) | 0.01 | 0.17 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 14.29 | 17.35 |
Price Performance
Historical Comparison SAMO
ZNTL
About SAMO Samos Energy Acquisition Corporation Class A Ordinary Shares
Samos Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.